International Journal of Clinical Pharmacy

, Volume 33, Issue 6, pp 886–894 | Cite as

Clinical pharmacists and basic scientists: do patients and physicians need this collaboration?

  • Amir H. Zargarzadeh
  • Susan Jacob
  • Roger S. KlotzEmail author
  • Fadi T. KhasawnehEmail author


The aim of this commentary is to highlight the vital and beneficial role that pharmacists and inter-professional collaborative practice play in patient care from the economic, humanistic, efficacy, and safety perspectives. Pharmacists, particularly those with an in-depth knowledge of the basic pharmaceutical sciences, recognize the need to collaborate with other healthcare professions and understand the importance of combining all of the components of their education into a well-rounded, comprehensive clinical practice. Indeed, there is ample evidence in the literature that pharmacists equipped with a solid foundation in basic pharmaceutical science, coupled with clinical knowledge and skills can, more effectively, contribute to pharmacotherapy and patient care, particularly in a collaborative practice setting. Consequently, the burden on pharmacy education is to maintain its emphasis on the basic sciences while promoting the application of these sciences in clinical practice, in the Pharm. D. curriculum. This is a goal that can also be achieved through inter-professional educational approaches.


Basic science Clinical pharmacy Inter-professional education Pharmacy education Patient outcomes 



The authors would like to thank Patricia Klotz, RN, and Dr. Wallace J. Murray for proofreading and editing the manuscript. The opinions, findings and conclusions herein are those of the author and not necessarily represent those The Regents of the University of California, or any of its programs.


This research was supported, in part, by funds provided by The Regents of the University of California, Tobacco-Related Disease Research Program, Grant Number 19KT-0030 (to F.T.K).

Conflicts of interests



  1. 1.
    Slone Survey. Patterns of medication use in the United States 2005. 2010. Accessed 20 Oct 2010.
  2. 2.
    IMS Health Report, 2010. 1 Apr 2010.Google Scholar
  3. 3.
    Truffer CJ, Keehan S, Smith S, Cylus J, et al. Health spending projections through 2019: the recession’s impact continues. Health Aff. 2010;29:522–9.CrossRefGoogle Scholar
  4. 4.
    World Health Organization 2000 Report. Health systems: improving performance. Geneva: World Health Organization. ISBN 92 4 156198 X.Google Scholar
  5. 5.
    American Academy of Family Physicians, American Academy of Pediatrics, American College of Physicians, American Osteopathic Association. Joint principles of the patient centered medical home [Internet]. Philadelphia: ACP; 2007. Accessed 23 Oct 2010.
  6. 6.
    National Committee for Quality Assurance [Internet]. Press release, NCQA program to evaluate patient-centered medical homes; PPC-PCMH to focus on care coordination, integration. Washington: NCQA; 2010. Available from: 23 Oct 2010.
  7. 7.
    Anaya JP, Rivera JO, Lawson K, Garcia J, et al. Evaluation of pharmacist managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health Syst Pharm. 2008;65:1841–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Bjornson DC, Hiner WO Jr, Potyk RP, Nelson BA, et al. Effect of pharmacist on health care outcomes in hospitalized patients. Am J Hosp Pharm. 1993;50:1875–84.PubMedGoogle Scholar
  9. 9.
    Bond CA, Raehl Cl. Clinical and economic outcomes of pharmacist managed antimicrobial prophylaxis in surgical patients. Am J Health Syst Pharm. 2007;64:1935–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Boyko WL Jr, Yurkowski PJ, Ivey MF, Armitstead JA, et al. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health Syst Pharm. 1997;45:1591–5.Google Scholar
  11. 11.
    Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc. 2008;48:203–11. 3p following 211.CrossRefGoogle Scholar
  12. 12.
    Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166:955–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Ponniah A, Anderson B, Shabkib S, Doecke CJ, et al. Pharmacists’ role in the post-discharge management of patients with heart failure: a literature review. J Clin Pharm Ther. 2007;32:343–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Roughead L, Semple S, Vitry A. The value of pharmacist professional services in the community setting. A systematic review of the literature 1990–2002. 2010. Accessed 10 Oct 2010.
  15. 15.
    Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29:691–8.PubMedGoogle Scholar
  16. 16.
    Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother. 1999;33:1336–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilization, costs and patient outcomes. Cochrane Database Syst. 2000; CD000336.Google Scholar
  18. 18.
    Blenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med. 2003;25:144–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28:421–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part I: systematic review and meta analysis in diabetes management. Ann Pharmacother. 2007;41:1569–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Morrison A, Wertheimer AI. Evaluation of studies investigating the effectiveness of pharmacists’ clinical services. Am J Health Syst Pharm. 2001;58:569–77.PubMedGoogle Scholar
  22. 22.
    Holland R, Desborough J, Goodyer L, Hall S, et al. Does pharmacist-led medication review help to reduce hospital admissions and death in older people? A systematic review and meta analysis. Br J Clin Pharmacol. 2008;65:303–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Pickard AS, Hung SY. An update on evidence of clinical pharmacy services’ impact on health-related quality of life. Ann Pharmacother. 2006;40:1623–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Machado M, Nassor N, Bajcar JM, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta analysis in hyperlipidemia management. Ann Pharmacother. 2008;42:1195–207.PubMedCrossRefGoogle Scholar
  25. 25.
    Doucette WR, Witrlky MJ, Farrisk KB, McDonough RP. Community pharmacist-provided extended diabetes care. Ann Pharmacother. 2009;43:882–9.PubMedCrossRefGoogle Scholar
  26. 26.
    McFarland MS, Cross LB, Gross B, Gentry C, et al. Drug use evaluation of Sitagliptin dosing by pharmacist versus non-pharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic. J Manag Care Pharm. 2009;15:563–7.PubMedGoogle Scholar
  27. 27.
    Taddei S, Bruno RM, Ghiadoni L. The correct administration of antihypertensive drugs according to the principles of clinical pharmacology. Am J Cardiovasc Drugs. 2011;11:13–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Machado M, Bajcar J, Guzzo GC, et al. Sensitivity of patient outcomes to pharmacist interventions. Part II: systematic review and meta analysis in hypertension management. Ann Pharmacother. 2007;41:1770–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Iyer R, Coderre P, McKelvey T, Cooper J, et al. An employer-based, pharmacist intervention model for patients with type 2 diabetes. Am J Health Syst Pharm. 2010;67:312–6.PubMedCrossRefGoogle Scholar
  31. 31.
    LaMarr B, Valdez C, Driscoll K, Ryan M. Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. Am J Health Syst Pharm. 2010;67:290–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc. 2009;49:164–70.CrossRefGoogle Scholar
  33. 33.
    Carter BL, Ardery G, Dawson JD, James PA, et al. Physician and Pharmacist collaboration to improve blood pressure control. Arch Intern Med. 2009;169:1996–2002.PubMedCrossRefGoogle Scholar
  34. 34.
    Weber CA, Ernst ME, Sezate GS, Zheng S, et al. Pharmacist-physician comanagement of hypertension and reduction in 24-hour ambulatory blood pressures. Arch Intern Med. 2010;170:1634–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Birtcher KK, Greisinger AJ, Brehm BJ, Wehmanen OA, et al. A secondary prevention lipid clinic reaches low-density lipoprotein cholesterol goals more often than usual cardiology care with coronary heart disease. J Clin Lipidol. 2010;4:46–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30:330–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Simpson SH, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, et al. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2011;34:20–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Bunting BA, Smith BH, Sutherland SE. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173–84.CrossRefGoogle Scholar
  39. 39.
    Smith M, Bates DW, Bodenheimer T, Cleary PD. Why pharmacists belong in the medical home. Health Aff. 2010;29:906–13.CrossRefGoogle Scholar
  40. 40.
    Ting HJ, Khasawneh FT. Glybenclamide: an antidiabetic with in vivo antithrombotic activity. Eur J Pharmacol. 2010;649:249–54.PubMedCrossRefGoogle Scholar
  41. 41.
    Nunez A, Gomez J, Zalba LR, Monton M, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst. 2000;1:175–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Basaria S, Coviello AD, Travison TG, Storer TW, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–22.PubMedCrossRefGoogle Scholar
  43. 43.
    Phillips GB. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:1866.PubMedGoogle Scholar
  44. 44.
    Chatterjee R, Yeh H-C, Shafi T. Serum and dietary potassium and risk of incident type 2 diabetes mellitus. Arch Intern Med. 2010;170:1745–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Sudano I, Flammer AJ, Périat D, Enseleit F, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010;122:1789–96.PubMedCrossRefGoogle Scholar
  46. 46.
    Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70:101.PubMedCrossRefGoogle Scholar
  47. 47.
    Newton DW. Science-based pharmacy education. Am J Pharm Educ. 2007;71:38.PubMedCrossRefGoogle Scholar
  48. 48.
    Ryu KH, Han HY, Lee SY, Jeon SD, et al. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thromb Res. 2009;124:328–34.PubMedCrossRefGoogle Scholar
  49. 49.
    Mohamed ME, Frye RF. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med; 2010 Nov 3 [ahead of print].Google Scholar
  50. 50.
    Zhu H, Butera M, Nelson D, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J. 2005;2:80.PubMedCrossRefGoogle Scholar
  51. 51.
    Cavallari LH, Overholser BR, Anderson D, Boyce E, et al. Recommended basic science foundation necessary to prepare pharmacists to manage personalized pharmacotherapy. Pharmacotherapy. 2010;30:228e–35e.CrossRefGoogle Scholar
  52. 52.
    McNair PP. The case for educating health care students in professionalism as the core content of inter-professional education. Med Educ. 2005;39:456–64.PubMedCrossRefGoogle Scholar
  53. 53.
    Chisholm-Burns MA, Lee JK, Spivey CA, Slack M, et al. US pharmacists effect as team members on patient care. Med Care. 2010;48:923–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesCollege of Pharmacy, Western University of Health SciencesPomonaUSA
  2. 2.Department of Pharmacy Practice and AdministrationCollege of Pharmacy, Western University of Health SciencesPomonaUSA

Personalised recommendations